



Investor Presentation

July 2024

Ticker: HVO



- The contents of this presentation and the information which you are given at the time of the presentation have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (the “Act”). Reliance on this presentation for the purpose of engaging in investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in hVIVO plc (the “Company”) nor shall it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in this presentation and/or opinions therein. This presentation is exempt from the general restriction (in section 21 of the Act) on the communication of invitations or inducements to engage in investment activity on the grounds that it is made to: (a) persons who have professional experience in matters relating to investments who fall within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (b) high net worth entities and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order; and (c) other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “relevant persons”). Any person (whether a relevant person or otherwise) is recommended to seek their own independent financial advice from a person authorised for the purposes of the Act before engaging in any investment activity involving the Company’s securities. Any recipient who is not a relevant person should return this presentation to the Company’s registered office and should not act upon it. By accepting this presentation and not immediately returning it, each recipient warrants, represents, acknowledges and agrees that it is a relevant person.
- This presentation does not constitute or form part of any offer or invitation or inducement to sell, issue, purchase or subscribe for (or any solicitation of any offer to purchase or subscribe for) the Company’s securities in the UK, US or any other jurisdiction and its distribution does not form the basis of, and should not be relied on in connection with, any contract or investment decision in relation thereto nor does it constitute a recommendation regarding the Company’s securities by the Company or its advisers and agents. Nothing in the presentation shall form the basis of any contract or commitment whatsoever. The distribution of this presentation outside the UK may be restricted by law and therefore persons outside the UK into whose possession this presentation comes should inform themselves about and observe any such restrictions as to the distribution of this presentation. The Company has not registered, and does not intend to register, any securities under the US Securities Act of 1933, as amended or to conduct a public offering of any securities in the US.
- This presentation contains “forward-looking” statements, beliefs, estimates, forecasts and opinions, including statements with respect to the business, financial condition, results of operations and plans of the Company and its group (“Group”). These forward-looking statements involve known and unknown risks and uncertainties, many of which are beyond the Company’s control and all of which are based on the current beliefs and expectations of the directors about future events. Recipients should note that past performance is not necessarily an indication of future performance and no assurance can be given that they will be attained. Forward-looking statements are sometimes identified by the use of forward-looking terminology such as “believes”, “expects”, “may”, “will”, “could”, “should”, “shall”, “risk”, “intends”, “estimates”, “aims”, “plans”, “predicts”, “continues”, “assumes”, “positioned” or “anticipates” or the negative thereof, other variations thereon or comparable terminology or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements may and often do differ materially from actual results.
- The significant risks related to the Company’s business which could cause the Company’s actual results and developments to differ materially from those forward-looking statements are discussed in the Company’s Annual Report and other filings. They appear in a number of places throughout this presentation and include statements regarding the intentions, beliefs or current expectations of the directors of the Company with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Group’s business, concerning, amongst other things, the results of operations, financial condition, prospects, growth and strategies of the Group and the industry in which it operates. No one will publicly update or revise any forward-looking statements or any other information contained herein, either as a result of new information, future events or otherwise.
- In considering the performance information contained herein, recipients should bear in mind that past performance is not necessarily indicative of future results, and there can be no assurance unrealised return projections will be met. Certain of the past performance information presented herein may not be representative of all transactions of a given type. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Group’s development strategies, the successful and timely completion of clinical studies, securing satisfactory licensing agreements for products, the ability of the Group to obtain additional financing for its operations and the market conditions affecting the availability and terms of such finances.
- The Company reports under IFRS. Where foreign currency equivalents have been provided for convenience in this presentation, the exchange rates applied are those used in the relevant financial statements from which the figures have been extracted. This presentation is confidential and is being supplied to each recipient of it solely for its information. While this presentation has been prepared in good faith, no representation, warranty, assurance or undertaking (express or implied) is or will be made, and no responsibility or liability is or will be accepted by the Company or by its officers, employees or agents in relation to the adequacy, accuracy, completeness or reasonableness of this presentation, or of any other information (whether written or oral), notice or document supplied or otherwise made available to any recipient. This presentation has been prepared to assist a recipient make its own evaluations and does not purport to be all-inclusive or contain all of the information a recipient may desire.

hVIVO


Venn Life Sciences
part of hVIVO


hLAB


FluCamp^o
Clinical Trials Recruitment



Who we are

A fast-growing specialist contract research organisation and the world leader in testing infectious and respiratory disease products using human challenge clinical trials

Mission

Delivering today's healthcare by empowering tomorrow's innovation.


Vision

To transform global healthcare by revolutionising the drug development process through scientific ingenuity.

What is a Human Challenge Trial?



A clinical trial where healthy volunteers are exposed to a pathogen to test the effectiveness of vaccine and treatments...



...in a faster and more efficient setting.

Benefits of Human Challenge Trials




Scientific

- Generates invaluable dosing, safety and efficacy data
- Helps optimise for larger field trials
- De-risks Phase III programs



Financial

- Significant valuation uplift for Biotech sponsor
- Quick, cost-effective data in a tight funding environment
- Allows products to “Succeed fast” or “Fail Fast”



Clinical Development

- Requires fewer subjects
- Significant time savings
- No seasonal dependence



Regulatory

- Potential for Fast Track or Breakthrough designation - accelerating time to market
- Potential approval and Emergency Use Authorisation

World Leading Human Challenge Model Offering



10 challenge agents manufactured in the past three years – investing in sustainable growth

	Influenza	RSV	HRV	Malaria	Asthma	SARS-CoV-2	hMPV	Dengue
Virus Strain	H3N2 Perth	Memphis 37b	HRV 14B	Plasmodium falciparum	HRV 14B/16A	Pre-Alpha	A2 strain	Dengue*
	H3N2 Wisconsin	New RSV B	HRV 16A			Delta		
	H5N1 attenuated	New RSV A				Omicron		
	H1N1 France							
	Flu B Victoria lineage							
	H3N2 England							

New to hVIVO in the past 2 years
 * *In development*
 Potential for the future: Norovirus, Zika, Pneumococcal

Record H1 revenue and EBITDA margin



H1 2024 Trading Update – July 2024

Revenue
£35.6m

H1 23: £27.3m
H1 22: £18.0m




EBITDA Margin
c.24%

H1 23: 19.1%
H1 22: 12.6%



Cash
£37.1m

H1 23: £31.3m
H1 22: £15.9m




Weighted
Orderbook
£71m

H1 23: £78m
H1 22: c.£70m




**Targeting £100m
Revenue by 2028**



Record H1 Revenue Growth

H1 2024 Trading Update – July 2024




Revenue

- 30% Revenue growth
- Acceleration of client projects
- Record number of volunteers inoculated
- Increase in challenge revenue per volunteer
- Six studies in quarantine across five different viruses
- Venn Life Sciences underlying revenue up 10%, accounts for 11% of total revenue
- £62m full year revenue guidance reaffirmed

An Increasingly Profitable Business

H1 2024 Trading Update – July 2024




EBITDA Margin

- Significant volume of work leads to margin uplift in H1 24
- Good utilisation of the overlapping facilities
- Significant Flucamp synergies delivering lower volunteer acquisition costs
- Includes manufacturing costs for replacement viruses & facility move costs
- Full year EBITDA margin at the upper end of market expectations

Cash Generative Business

H1 2024 Trading Update – July 2024



Cash

- Strong cash position as at 30 June 2024
- Increase in working capital following accelerated delivery of projects
- Timing of new deals and receipt of upfront booking fees
- Includes £1.4m dividend paid in May 24
- No debt

hVIVO's Growing & World Leading Services



End-to-End Human
Challenge Trial
Services



Specialist Analytic
Lab Services



Clinical Site
Services




Patient
Recruitment
Services

New facility providing the foundation and capacity for future growth

The World's Largest Human Challenge Trial Unit



 Floor 25, Canary Wharf

 **>90% Client Funded**


 **Reduced Aggregate Rent per m²**

 **16% More Space >30% Usable Space**

 **10-Year Lease 5-Year Break Rent Cap in Place**



50 Individual Negative Pressure Isolation Rooms


 **State-of-the-Art Call System**


 **Fully Fitted Kitchen & Food App**

 **>1,000 Monitoring Points**

 **100 HEPA Filters**

 **4 Separate Power Supplies**

 **Pneumatic Chute System**




- Staff Space
- Kitchen
- Outpatient Unit
- Quarantine Beds
- Airlock
- IMP Storage


Consolidation of Quarantine Facilities



Improved resource utilisation



hLab – Increased Capacity



Case Study: Phase 2b Field Study



- **Multinational trial**
Sites in US and UK, hVIVO selected as a sole UK site
- **FluCamp**
Enrolling up to 1,000 volunteers in 8 weeks

Generic Screening Programme Ongoing



Flexible Resourcing Model



Dedicated Volunteer Screening Site



10 Site Data Entry Team



Expansion of Out-Patient Unit to Facilitate Future Field Studies

Increasing Vaccination Capacity from 100 to 200 volunteers per week



To Complete Q3 24

Different Collaboration Scenarios


Full-Scope Phase II studies

Acting as a Site in large Phase II-III studies

Stand-alone Recruitment Services (subject referral)

FLUCAMP DATABASE

Database of engaged and motivated participants



TIERED RECRUITMENT OFFERING



CASE STUDY – RECENT CONTRACT

FluCamp approached by a large Global CRO to support with a difficult to recruit population

Target of 50 referrals


- ✓ Essential package - database review & outreach
- ✓ 98% of participants engaged gave consent
- ✓ All 50 referrals completed within 4 weeks
- ✓ Discussion on moving to Advance model




Venn Life Sciences Service Offering



Gap Analysis, Due diligence




Regulatory Affairs




Diverse and Growing Sales Pipeline


**Pipeline Distribution
by Region**




**Pipeline Distribution
by Client Type**



**Pipeline Distribution
by Service**



**Pipeline Distribution
by Model**



Continued Delivery

- Strong revenue, EBITDA, and sales
- Robust cash position
- Record inoculations
- Improving operational efficiencies and margins

Scaling & Driving Efficiencies

- New 50-bedroom facility
- Increased lab & outpatient capacity
- New challenge models
- New services
- Improved automation

Well Positioned for Future Growth

- Guiding £62m revenue 2024 & EBITDA margins at upper end of market expectations
- £71m weighted contracted orderbook
- 100% of 2024 revenue contracted & good visibility into 2025
- Medium-term target of £100m revenue

A long-term sustainable growth model



World Leading Capabilities



Expanding Market



High Barrier to Entry



Strongest Ever Sales Pipeline



Appendix

Ticker: HVO



Conducting Trials with Hazard Group 3 Pathogens

Rooms are built to hospital isolation standards with HEPA filters on all air extracts in each isolation room

Air Handling Unit

- Maintains negative pressure in each room
- Between -5 and -15 pascals
- 8-10 air changes per hour
- The failover system

Back up Power

- Building is connected to 2 separate power station via 4 power lines
- Should the power from all 4 lines fail, there are back-up generators on the roof

State-of-the-Art *h*LAB Facilities at Canary Wharf



Previous Site	Previous Site	Canary Wharf
246m ²	Usable Lab Space	580m ²
3 rd Party	CL3 Lab	✓ In House
-	Automated Sample Dispatch	✓
3 rd Party	Autoclave Room	✓ In House
-	Dedicated Storeroom	✓
-	Additional Flexible Lab Space	✓



Strategy to Grow *h*LAB brand



Brand Awareness

- *h*LAB is a leader in virology clinical trial support
- Dedicated website
- Conferences



Scientific Expansion

- Large expansion in assay portfolio to include new specialties and Biospecimen Services



Growth

- Targeting year-on-year growth of standalone *h*LAB services
- Increased lab capacity
- Increase in subject matter experts




Systems & Technology

- Increased automation: PCR & Cell culture
- LIMS & eSource integration

VOLUNTEER JOURNEY

Lead to inoculation - 2023



<math><0.5\%</math>
enrolled onto a challenge trial

Recruitment
30 – 40% of trial budget

Managing costs at each step

- Strict invite requirements
- Real time analytics
- Expertise of the virus model


High barrier to entry due to volumes

FLUCAMP AS A SERVICE



- **Loyal volunteer community**
- Collaborate on material generation
- 135 User Generated Content



- **Key partnerships**
- Access to 7 million primary care patients



- **Latest technological solutions**




FLUCAMP PORTAL

Launch 2024!

LIVE DATABASE ACCESSIBLE BY CLIENTS



**DRIVING ENGAGEMENT,
REFERRALS &
REGISTRATIONS**



Scan for Video



hVIVO

Stay in touch



Ticker: HVO